PTPRC and infection: In SIV and HIV immunization studies, much of the capacity to enhance susceptibility to infection has been attributed to an increase in general immune activation and/or expansion of lymphoid target cells, and this feature has also been observed in FIV studies.29,43,64–68 Flow cytometry analysis of lymphoid immunophenotypes in Protocol II identified significant variations in CD4+, CD8+, and B220+ lymphocytes among CD134 and CD134+SU treatment groups prior to infection (Fig. 5).